Clinical Research Directory
Browse clinical research sites, groups, and studies.
Finerenone Plus SGLT2 Inhibitors in Heart Failure
Sponsor: Mansoura University
Summary
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure. The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone. Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.
Official title: Impact of Finerenone in Combination With Sodium Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-01-18
Completion Date
2026-07-31
Last Updated
2026-01-20
Healthy Volunteers
No
Conditions
Interventions
Finerenone
Finerenone administered orally at a dose of 10 mg once daily.
dapagliflozine
Dapagliflozin administered orally at a dose of 10 mg once daily.
Locations (1)
Mansoura University Hospitals, Cardiology Department (Specialized Medical Hospital)
Al Mansurah, Egypt